Company Overview of Viroxis Corporation
ViroXis Corporation develops and markets prescription and over-the-counter botanical products for the treatment of virally-induced skin conditions. The company was founded in 2006 and is based in San Antonio, Texas. As of August 4, 2015, ViroXis Corporation operates as a subsidiary of TFS Corporation Ltd.
12621 Silicon Drive
San Antonio, TX 78249
Founded in 2006
Key Executives for Viroxis Corporation
Co-Founder, Chief Executive Officer and President
President of Management Associates and Principal of Management Associates
Compensation as of Fiscal Year 2015.
Viroxis Corporation Key Developments
ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product
Feb 26 14
ViroXis Corporation announced the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an over-the-counter (OTC) sandalwood oil-containing product. The long-term agreement includes a licensing fee, milestone payments and royalties based on product sales. The pharmaceutical partner is exclusively dedicated to dermatology and is a world leader in dermatology products with an extensive product portfolio available in 80 countries. The license agreement anticipates worldwide commercialization of the OTC product, with an initial product launch in the U.S. anticipated in early 2015. ViroXis has completed an open label Phase 2 study to support the launch of its OTC product, and a publication describing the study is in preparation. A second OTC product is in development.
ViroXis Corporation Completes Clinical Study Using TFS Sandalwood Oil
Feb 18 14
ViroXis Corporation announced that the last patient has completed treatment in the company's 183 patient phase 2 clinical study of an East Indian Sandalwood Oil (EISO) based therapy for HPV/common skin warts. There will now be a three-month follow-up period before the final primary efficacy endpoint is measured. Based on this timeline, the complete data set will be known mid-year. The ElSO-based treatment was very well tolerated, with few adverse events reported. Viroxis plans to meet with the Federal Drug Administration (FDA) and look to move toward their objective of conducting Phase 3 approval trials for a prescription HPV/Wart treatment. In the US, the prevalence of HPV/common warts is thought to be as high as 10% in certain populations. The company can also announce that, based on FDA feedback, it can initiate a new placebo controlled, phase 2 clinical study for the treatment of Molluscum contigiosum (MCV) in a pediatric population. MCV is a very prevalent, highly contagious pox virus infection of the skin, mainly affecting children. There are currently no approved prescription treatments for MCV and the disease presents a high clinical and patient burden.
Viroxis Corporation Provides Pharmaceutical Development Update
Oct 1 13
ViroXis Corporation has completed enrolment (176 patients) in its Federal Drug Administration (FDA) approved phase 2 clinical study of its Prescription HPV/skin wart treatment. The study results should be known in second quarter of calendar 2014. This FDA process is the first of two Investigational New Drug (IND) applications based on TFS Santalum album oil that Viroxis is pursuing.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 18, 2015
Most Searched Private Companies
Sponsored Financial Commentaries